Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Novel transcript, antisense to YARS2" (ENSG00000286950) is a non-coding genomic region annotated as transcribed in the antisense orientation relative to the YARS2 gene, which encodes mitochondrial tyrosyl-tRNA synthetase[4][2][1]. There is no evidence in the current literature or genomics databases that this antisense transcript produces a functional protein or acts as a direct therapeutic target. It is not classified as a receptor, enzyme, transporter, or other druggable protein. Information on function, disease association, drugs, or clinical utility for this transcript is lacking, as is evidence of its use as a biomarker or its involvement in safety or therapeutic concerns. This entry represents an uncharacterized or hypothetical transcript rather than a validated molecular target. YARS2 (the sense gene) is a well-studied mitochondrial enzyme with involvement in mitochondrial protein synthesis and various diseases including mitochondrial myopathies and potentially certain cancers[1][2][4], but the antisense transcript to YARS2 has no established role or characterization in molecular biology or medicine. It is not uncommon for large-scale genomic annotation projects to predict or annotate antisense and non-coding transcripts without clear evidence of functional relevance. ENSG00000286950 appears to be such a prediction, with no current evidence of a biological, pharmacological, or clinical role.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, antisense to YARS2.